Please login to the form below

Not currently logged in
Email:
Password:

Glycotope appoints Dr Alfredo Zurlo as chief medical officer

He joins the German clinical-stage immuno-oncology company from Mologen

Glycotope Alfredo ZurloGerman clinical-stage immuno-oncology company Glycotope has appointed Dr Alfredo Zurlo as chief medical officer.

He joins the firm from Mologen AG, where he was its chief medical officer and a member of the Berlin-based biotech's executive board.

Prior that Dr Zurlo held various positions at F Hoffmann La Roche and Roche SA, including senior international medical leader director oncology and medical director oncology.

Previous to his time at Roche he was a medical advisor for the European Organisation for the Research and Treatment of Cancer (EORTC).

Glycotope's chief executive officer Paul Higham said: “We are delighted that Alfredo has decided to join Glycotope. He has an exceptionally strong background in oncology both in a clinical setting and within companies developing and marketing treatments for cancer.

“His experience in designing and managing clinical trials will be invaluable as we continue to advance our mature and growing pipeline of proprietary cancer therapies including our oncology lead PankoMab-GEX which is currently in phase IIb in ovarian cancer.“

11th May 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...